The Journal of Rheumatology is not responsible or liable for the content of the supplementary material, which has been supplied by the author(s).

Supplementary Table 1. Measurement and definitions of remission

2016 preliminary gout remission definition	
Three-monthly measurements of remission	**Six-monthly measurements of remission**
Absence of gout flares during the following periods of follow-up: (First three months) Months 1 to 3 (Second three months) Months 4 to 6 (Third three months) Months 7 to 9 (Last three months) Months 10 to 12	Absence of gout flares during the following periods of follow-up: (First six months) Months 1 to 6 (Last six months) Months 7 to 12
Serum urate ≤0.36mmol/L at the following periods of follow-up: (First three months) Month 3 (Second three months) Month 6 (Third three months) Month 9 (Last three months) Month 12	Serum urate ≤0.36mmol/L, no values >0.36mmol/l at the following periods of follow-up: (First six months) Months 3 and 6 (Last six months) Months 9 and 12
Absence of tophi at the end of each three-monthly period of follow-up.	Absence of tophi at the end of each six-monthly period of follow-up.
Pain VAS <20mm, no values ≥20mm at the following periods of follow-up: (First three months) Month 3 (Second three months) Month 6 (Third three months) Month 9 (Last three months) Month 12	Pain VAS <20mm, no values ≥20mm at the following periods of follow-up: (First six months) Months 3 and 6 (Last six months) Months 9 and 12
Patient global assessment <20mm, no values ≥20mm at the following periods of follow-up: (First three months) Month 3 (Second three months Month 6 (Third three months) Month 9 (Last three months) Month 12	Patient global assessment <20mm, no values ≥20mm at the following periods of follow-up: (First six months) Months 3 and 6 (Last six months) Months 9 and 12

The Journal of Rheumatology is not responsible or liable for the content of the supplementary material, which has been supplied by the author(s).

Simplified gout remission definition

Absence of gout flares during the following periods of follow-up: (First three months) Months 1 to 3 (Second three months) Months 4 to 6 (Third three months) Months 7 to 9 (Last three months) Months 10 to 12	Absence of gout flares during the following periods of follow-up: (First six months) Months 1 to 6 (Last six months) Months 7 to 12
Serum urate ≤0.36mmol/L at the following periods of follow-up: (First three months) Month 3 (Second three months) Month 6 (Third three months) Month 9 (Last three months) Month 12	Serum urate ≤0.36mmol/L, no values >0.36mmol/l at the following periods of follow-up: (First six months) Months 3 and 6 (Last six months) Months 9 and 12
Absence of tophi at the end of each three-monthly period.	Absence of tophi at the end of each six-monthly period.

The Journal of Rheumatology is not responsible or liable for the content of the supplementary material, which has been supplied by the author(s).

Supplementary Table 2. Baseline characteristics of participants. Unless stated, data are shown as mean (SD). Modified from (12) with permission.

	Colchicine N=100	**Placebo N=100**	**Total N=200**
Age (years)	54.8 (16.0)	57.1 (15.3)	56.0 (15.7)
Gender (female/male)	8/92	6/94	14/186
Ethnicity, n (%)			
Asian	17 (17.0%)	9 (9.0%)	26 (13.0%)
Māori	12 (12.0%)	11 (11.0%)	23 (11.5%)
NZ European	51 (51.0%)	69 (69.0%)	120 (60.0%)
Other	2 (2.0%)	1 (1.0%)	3 (1.5%)
Pacific peoples	18 (18.0%)	10 (10.0%)	28 (14.0%)
Disease duration (years)	10.7 (8.8)	12.4 (11.1)	11.2 (10.1)
Body mass index (kg/m^2)	33.2 (8.0)	31.3 (6.5)	32.3 (7.3)
Gout flare frequency in preceding month, median (IQR)	1 (0 to 1)	1 (0 to 2)	1 (0 to 1)
Gout flare frequency in preceding six month, median (IQR)	2 (2 to 4)	2 (1 to 4)	2 (2 to 4)
Serum urate (mmol/l)	0.52 (0.09)	0.48 (0.07)	0.50 (0.08)
Presence of subcutaneous tophi n (%)	26 (26.0%)	23 (23.0%)	49 (24.5%)
Pain VAS (0-100 mm)	11.9 (18.9)	13.7 (21.0)	12.8 (20.0)
Patient global assessment VAS mm (0-100 mm)	24.9 (19.9)	22.3 (16.7)	23.6 (18.4)
Creatinine (mmol/l)	94.0 (17.0)	92.8 (19.1)	93.4 (18.0)
eGFR ($mL/min/1.73m^2$)	77.4 (16.3)	77.4 (16.5)	77.4 (16.3)
Comorbidities n (%)			
Obesity*	60 (60.0%)	49 (49.0%)	109 (54.5%)
eGFR <60mls/min/$1.73m^2$	14 (14.0%)	15 (15.0%)	29 (14.5%)
Kidney stones	6 (6.0%)	12 (12.0%)	18 (9.0%)
Cardiovascular disease ‡	18 (18.0%)	22 (22.0%)	40 (20.0%)
Type 2 diabetes	5 (5.0%)	8 (8.0%)	13 (6.5%)
Hypertension	44 (44.0%)	45 (45.0%)	89 (44.5%)
Hyperlipidemia	32 (32.0%)	35 (35.0%)	67 (33.5%)
Concurrent medications			
Diuretic	16 (16.0%)	10 (10.0%)	26 (13.0%)
Aspirin	17 (17.0%)	15 (15.0%)	32 (16.0%)

*Obesity defined as BMI ≥30 kg/m^2
‡CVD defined as ischemic heart disease, heart failure or peripheral vascular disease
BMI, body mass index; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate

The Journal of Rheumatology is not responsible or liable for the content
of the supplementary material, which has been supplied by the author(s).











Supplementary Figure 1. Fulfilment of the individual remission domains by intervention over three monthly periods. Domains were defined as follows: Absence of gout flares over months 1-3, months 4-6, months 7-9 and months 10-12; Serum urate ≤0.36mmol/l at month 3, month 6, month 9 and month 12; Absence of tophi at month 3, month 6, month 9 and month 12; pain <20mm and patient global assessment <20mm at month 3, month 6 month 9 and month 12.